Literature DB >> 27027964

Sputum Gene Expression of IL-13 Receptor α2 Chain Correlates with Airflow Obstruction and Helper T-Cell Type 2 Inflammation in Asthma.

Vera Nezgovorova1, Qing Liu1, Bugu Hu1, Jose L Gomez Villalobos1, Xiting Yan1, Naigian Niu1, Carole Holm1, Nicole P Grant1, Sarah Marone1, Lois Ravage-Mass1, Chun Geun Lee2, Jack A Elias2, Lauren Cohn1, Geoffrey L Chupp1.   

Abstract

BACKGROUND: BRP-39/YKL-40 is a chitinase-like protein that plays a critical role in IL-13-induced inflammation. It correlates positively with asthma severity and airway remodeling ( 1 ) via binding to IL-13 receptor α2 chain (IL-13Rα2). Because the relationship of IL-13Rα2 to human asthma has never been evaluated previously, we sought to determine the relationship between IL-13Rα2, YKL-40, and asthma.
METHODS: We evaluated 112 patients (69% women) with a mean age of 46.7 years. Subjects completed an asthma phenotyping protocol that included analysis of sputum gene expression by Affymetrix 1.0 ST gene array (Affymetrix, Santa Clara, CA) and YKL-40 protein levels.
MEASUREMENTS AND MAIN RESULTS: IL-13Rα2 gene expression was readily detectable in the sputum and correlated negatively with prebronchodilator (BD) FEV1 (rs = -0.282, P < 0.01), post-BD FEV1 (rs = -0.268, P < 0.01), pre-BD FEV1/FVC ratio (rs = -0.228, P < 0.05), and post-BD FEV1/FVC ratio (rs = -0.242, P < 0.01). IL-13Rα2 gene expression correlated positively with gene expression of IL-13 (rs = 0.484, P < 0.001), IL-5 (rs = 0.237, P < 0.05), and IL-8 (rs = 0.218, P < 0.05). Regression analysis showed that the post-BD FEV1/FVC ratio is significantly associated with IL-13Rα2 expression and CHI3L1 expression in sputum after controlling for IL-4, IL-5, IL-13, and transforming growth factor-β1 gene expression (all P < 0.01). Sputum YKL-40 gene expression positively correlated with IL-8 expression (rs = 0.357, P < 0.001) and negatively correlated with pre- and post-BD FEV1/FVC ratios (rs = -0.299, P < 0.001 and rs = -0.305, P < 0.01, respectively). Sputum and serum YKL-40 protein levels were not associated with IL-13Rα2 expression.
CONCLUSIONS: This analysis demonstrates that IL-13Rα2 is associated with reduced lung function, helper T-cell type 2 gene expression, and airflow obstruction in the airway of individuals with asthma, which might in turn be driven by airway remodeling. Future studies will be required to define the proinflammatory and remodeling effects of this receptor that up to now has been considered solely a modulator of IL-13-induced inflammation.

Entities:  

Year:  2016        PMID: 27027964      PMCID: PMC5015742          DOI: 10.1513/AnnalsATS.201509-611MG

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  1 in total

1.  A chitinase-like protein in the lung and circulation of patients with severe asthma.

Authors:  Geoffrey L Chupp; Chun Geun Lee; Nizar Jarjour; Yun Michael Shim; Carole T Holm; Susan He; James D Dziura; Jennifer Reed; Anthony J Coyle; Peter Kiener; Mark Cullen; Martine Grandsaigne; Marie-Christine Dombret; Michel Aubier; Marina Pretolani; Jack A Elias
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

  1 in total
  3 in total

1.  Chitinase 3-like-1 is produced by human Th17 cells and correlates with the level of inflammation in juvenile idiopathic arthritis patients.

Authors:  Manuela Capone; Laura Maggi; Veronica Santarlasci; Maria Caterina Rossi; Alessio Mazzoni; Gianni Montaini; Rolando Cimaz; Matteo Ramazzotti; Marie Pierre Piccinni; Giusi Barra; Raffaele De Palma; Francesco Liotta; Enrico Maggi; Sergio Romagnani; Francesco Annunziato; Lorenzo Cosmi
Journal:  Clin Mol Allergy       Date:  2016-11-08

Review 2.  New perspectives on the regulation of type II inflammation in asthma.

Authors:  Mireya Becerra-Díaz; Marsha Wills-Karp; Nicola M Heller
Journal:  F1000Res       Date:  2017-06-28

Review 3.  Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Authors:  Martin Braddock; Nicola A Hanania; Amir Sharafkhaneh; Gene Colice; Mats Carlsson
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.